S&P 500: 681.75 +0.1% NASDAQ 100: 601.92 +0.2% Dow Jones: 495.28 +0.1%

Jefferies Group’s FOLD Holdings & Trades

First Buy
Q2 2023
Duration Held
8 Quarters
Largest Add
Q1 2025
+187,897 Shares
Current Position
165,485 Shares
$2.36 M Value

Jefferies Group's FOLD Position Overview

Jefferies Group (via Jefferies Financial Group Inc.) currently holds 165,485 shares of Amicus Therapeutics, Inc. (FOLD) worth $2.36 M, representing 0.01% of the portfolio. First purchased in 2023-Q2, this short-term holding has been held for 8 quarters.

Based on 13F filings, Jefferies Group has maintained this position in FOLD for several quarters, showing initial confidence in the investment. Largest addition occurred in Q1 2025, adding 187,897 shares. Largest reduction occurred in Q3 2025, reducing 58,315 shares.

Analysis based on 13F filings available since 2013 Q2

Jefferies Group's Amicus Therapeutics (FOLD) Holding Value Over Time

Track share changes against reported price movement

Quarterly Amicus Therapeutics (FOLD) Trades by Jefferies Group

Report Date Bought/Sold (Sh.) % Change Qtr. End Shares Reported Price
Q2 2023 +92,285 New Buy 92,285 $12.56
Q3 2023 -38,512 Reduce 41.73% 53,773 $12.16
Q4 2023 -24,279 Reduce 45.15% 29,494 $14.19
Q1 2024 -29,494 Sold Out 0 $0.00
Q1 2025 +187,897 New Buy 187,897 $8.16
Q2 2025 +35,903 Add 19.11% 223,800 $5.73
Q3 2025 -58,315 Reduce 26.06% 165,485 $7.88

Jefferies Group's Amicus Therapeutics Investment FAQs

Jefferies Group first purchased Amicus Therapeutics, Inc. (FOLD) in Q2 2023, acquiring 92,285 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.

Jefferies Group has held Amicus Therapeutics, Inc. (FOLD) for 8 quarters since Q2 2023.

Jefferies Group's largest addition to Amicus Therapeutics, Inc. (FOLD) was in Q1 2025, adding 187,897 shares worth $1.53 M.

According to the latest 13F filing for Q4 2025, Jefferies Group's firm, Jefferies Financial Group Inc., owns 165,485 shares of Amicus Therapeutics, Inc. (FOLD), valued at approximately $2.36 M.

As of the Q4 2025 filing, Amicus Therapeutics, Inc. (FOLD) represents approximately 0.01% of Jefferies Group's publicly disclosed stock portfolio, making it one of their key holdings.

Jefferies Group's peak holding in Amicus Therapeutics, Inc. (FOLD) was 223,800 shares, as reported at the end of Q2 2025.